. 2013 Dec 22;9(11):1798–1807. doi: 10.1093/scan/nst175

Table 2.

ROI analyses: group × valence interaction effects

A priori regions	Mixed-effects analysis group × valence interaction	Pairwise comparisons: MDD > CON
A priori regions	Mixed-effects analysis group × valence interaction	Accept	Reject
R amygdala	F_{(1, 305)} = 17.91^***, η² = 0.06	t₍₄₆₎ = 0.35, P = 0.73	t₍₄₆₎ = 2.13, P = 0.04*, d = 0.62
L amygdala	F_{(1, 274)} = 28.91^***, η² = 0.10	t₍₄₆₎ = 1.26, P = 0.22	t₍₄₆₎ = 2.21, P = 0.03*, d = 0.64
sgACC	F_{(1, 298)} = 28.01^***, η² = 0.09	t₍₄₆₎ = 0.32, P = 0.75	t₍₄₆₎ = 3.06, P = 0.00**, d = 0.89
R anterior insula	F_{(1, 422)} = 3.24, η² = 0.01	t₍₄₆₎ = 0.04, P = 0.97	t₍₄₆₎ = 0.94, P = 0.35, d = 0.27
L anterior insula	F_{(1, 393)} = 19.40^***, η² = 0.05	t₍₄₆₎ = 0.13, P = 0.90	t₄₆₎ = 2.03, P = 0.05*, d = 0.59
R NAcc	F_{(1, 326)} = 3.94, η² = 0.01	t₍₄₆₎ = 0.55, P = 0.59	t₍₄₆₎ = 2.04, P = 0.05*, d = 0.59
L NAcc	F_{(1, 320)} = 16.15^***, η² = 0.05	t₍₄₆₎ = 0.10, P = 0.92	t₍₄₆₎ = 2.47, P = 0.02*, d = 0.72
R VLPFC	F_{(1, 375)} = 13.29^***, η² = 0.03	t₍₄₆₎ = 0.32, P = 0.75	t₍₄₆₎ = 1.68, P = 0.10, d = 0.50
L VLPFC	F_{(1, 408)} = 11.29^***, η² = 0.03	t₍₄₆₎ = 0.14, P = 0.89	t₍₄₆₎ = 1.59, P = 0.12, d = 0.46
mPFC	F_{(1, 368)} = 2.05, η² = 0.01	t₍₄₆₎ = 0.87, P = 0.39	t₍₄₆₎ = 1.86, P = 0.07, d = 0.54
vACC	F_{(1, 314)} = 8.36^***, η² = 0.03	t₍₄₆₎ = 0.10, P = 0.92	t₍₄₆₎ = 1.68, P = 0.10, d = 0.50

***P < 0.005 (Bonferroni corrected P-value for mixed effects F-tests), **P < 0.01, *P < 0.05; d, Cohen’s d effect size (0.20 = small, 0.50 = medium, 0.8 = large); η², eta-squared effect size (0.01 = small, 0.06 = medium, 0.14 = large). ROI analyses were repeated excluding the two participants taking SSRI medications and all results were replicated, with the exception of the group × valence interaction effect in the vACC, which was no longer significant [F_{(1, 302)} = 5.98, P = 0.02, η² = 0.02].